Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) Treated in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis

Presented on November 26, 2018

Brian S. Metzger, MD, MPH – Austin Infectious Disease Consultants, Austin, TX
John S. Adams, MD, FIDSA, FSHEA – Knoxville Infectious Disease Consultants, P.C., Knoxville, TN
Jorge R. Bernett, MD – Infectious Disease Doctors Medical Group, Walnut Creek, CA
Richard M. Mandel, MD, FIDSA – Southern Arizona Infectious Disease Specialists, PLC, Tucson, AZ
Richard C. Prokesch, MD, FACP, FIDSA – Infectious Diseases Associates, Riverdale, GA
Carson T Lo, MD – West Houston Infectious Disease Associates, Katy, TX
Thomas C Hardin, PharmD – Healix Infusion Therapy, Sugar Land, TX
Claudia P Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc, Sugar Land, TX

View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.